10 20 30 40 50 60 70 80 2O1Y - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER APOPTOSIS 29-NOV-06 2O1Y
TITLE SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN TITLE 2 COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND
COMPND MOL_ID: 1; COMPND 2 MOLECULE: APOPTOSIS REGULATOR BCL-X; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: BCL-2-LIKE 1 PROTEIN; COMPND 5 ENGINEERED: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET30B
KEYWDS APOPTOSIS, COMPLEX, BCL, NMR
EXPDTA SOLUTION NMR
AUTHOR M.BRUNCKO,T.K.OOST,B.A.BELLI,H.DING,M.K.JOSEPH,A.KUNZER, AUTHOR 2 D.MARTINEAU,W.J.MCCLELLAN,M.MITTEN,S.C.NG,P.M.NIMMER, AUTHOR 3 T.OLTERSDORF,C.M.PARK,A.M.PETROS,A.R.SHOEMAKER,X.SONG, AUTHOR 4 X.WANG,M.D.WENDT,H.ZHANG,S.W.FESIK,S.H.ROSENBERG,S.W.ELMORE
REVDAT 2 24-FEB-09 2O1Y 1 VERSN REVDAT 1 27-FEB-07 2O1Y 0
JRNL AUTH M.BRUNCKO,T.K.OOST,B.A.BELLI,H.DING,M.K.JOSEPH, JRNL AUTH 2 A.KUNZER,D.MARTINEAU,W.J.MCCLELLAN,M.MITTEN,S.C.NG, JRNL AUTH 3 P.M.NIMMER,T.OLTERSDORF,C.M.PARK,A.M.PETROS, JRNL AUTH 4 A.R.SHOEMAKER,X.SONG,X.WANG,M.D.WENDT,H.ZHANG, JRNL AUTH 5 S.W.FESIK,S.H.ROSENBERG,S.W.ELMORE JRNL TITL STUDIES LEADING TO POTENT, DUAL INHIBITORS OF JRNL TITL 2 BCL-2 AND BCL-XL. JRNL REF J.MED.CHEM. V. 50 641 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17256834 JRNL DOI 10.1021/JM061152T
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER A. T. ETALL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 2O1Y COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-DEC-06. REMARK 100 THE RCSB ID CODE IS RCSB040584.
REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 7.0 REMARK 210 IONIC STRENGTH : 50 MM SODIUM PHOSPHATE REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : 50MM SODIUM PHOSPHATE BUFFER; REMARK 210 90% H2O, 10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D_13C-SEPARATED_NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ, 800 MHZ REMARK 210 SPECTROMETER MODEL : DRX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : NULL REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : NULL REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL
REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 GLU A 162 CD GLU A 162 OE2 0.110 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 193 CB - CG - OD2 ANGL. DEV. = -5.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 MET A 3 156.87 171.15 REMARK 500 ALA A 4 -152.48 -139.64 REMARK 500 TYR A 26 -172.96 -67.90 REMARK 500 SER A 27 -89.62 176.05 REMARK 500 TRP A 28 140.02 62.69 REMARK 500 SER A 29 -158.75 -179.91 REMARK 500 SER A 32 -175.76 -171.08 REMARK 500 VAL A 34 -97.03 -143.66 REMARK 500 GLU A 35 118.66 170.52 REMARK 500 ARG A 38 154.22 176.21 REMARK 500 THR A 39 80.75 -176.48 REMARK 500 GLU A 40 -73.85 -159.16 REMARK 500 ALA A 41 99.06 179.90 REMARK 500 THR A 45 130.22 58.37 REMARK 500 SER A 47 -151.76 -91.49 REMARK 500 GLU A 48 50.27 -170.48 REMARK 500 ALA A 89 -149.51 -135.71 REMARK 500 LYS A 91 -72.25 -38.09 REMARK 500 ARG A 169 -73.61 -66.27 REMARK 500 HIS A 181 10.65 -143.39 REMARK 500 LEU A 182 -45.07 -148.66 REMARK 500 ASP A 193 -31.17 -35.85 REMARK 500 LEU A 198 -71.59 -118.86 REMARK 500 TYR A 199 53.15 -102.36 REMARK 500 ASN A 201 -85.25 -43.48 REMARK 500 ASN A 202 -33.85 -36.00 REMARK 500 HIS A 217 -72.48 -65.82 REMARK 500 REMARK 500 REMARK: NULL
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 43B A 1000
DBREF 2O1Y A 5 48 UNP Q07817 BCLX_HUMAN 1 44 DBREF 2O1Y A 89 213 UNP Q07817 BCLX_HUMAN 85 209
SEQADV 2O1Y MET A 1 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y SER A 2 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y MET A 3 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y ALA A 4 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y LEU A 214 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y GLU A 215 UNP Q07817 CLONING ARTIFACT SEQADV 2O1Y HIS A 216 UNP Q07817 EXPRESSION TAG SEQADV 2O1Y HIS A 217 UNP Q07817 EXPRESSION TAG SEQADV 2O1Y HIS A 218 UNP Q07817 EXPRESSION TAG SEQADV 2O1Y HIS A 219 UNP Q07817 EXPRESSION TAG SEQADV 2O1Y HIS A 220 UNP Q07817 EXPRESSION TAG SEQADV 2O1Y HIS A 221 UNP Q07817 EXPRESSION TAG
SEQRES 1 A 181 MET SER MET ALA MET SER GLN SER ASN ARG GLU LEU VAL SEQRES 2 A 181 VAL ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY TYR SEQRES 3 A 181 SER TRP SER GLN PHE SER ASP VAL GLU GLU ASN ARG THR SEQRES 4 A 181 GLU ALA PRO GLU GLY THR GLU SER GLU ALA VAL LYS GLN SEQRES 5 A 181 ALA LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR SEQRES 6 A 181 ARG ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE SEQRES 7 A 181 THR PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL SEQRES 8 A 181 ASN GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE SEQRES 9 A 181 VAL ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SEQRES 10 A 181 SER VAL ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE SEQRES 11 A 181 ALA ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU SEQRES 12 A 181 PRO TRP ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL SEQRES 13 A 181 GLU LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS SEQRES 14 A 181 GLY GLN GLU ARG LEU GLU HIS HIS HIS HIS HIS HIS
HET 43B A1000 78
HETNAM 43B 3-NITRO-N-{4-[2-(2-PHENYLETHYL)-1,3-BENZOTHIAZOL-5- HETNAM 2 43B YL]BENZOYL}-4-{[2-(PHENYLSULFANYL) HETNAM 3 43B ETHYL]AMINO}BENZENESULFONAMIDE
FORMUL 2 43B C36 H30 N4 O5 S3
HELIX 1 1 GLN A 7 GLN A 23 1 17 HELIX 2 2 ALA A 89 TYR A 105 1 17 HELIX 3 3 TYR A 105 SER A 114 1 10 HELIX 4 4 ALA A 123 LEU A 134 1 12 HELIX 5 5 ASN A 140 LYS A 161 1 22 HELIX 6 6 GLN A 164 LEU A 178 1 15 HELIX 7 7 LEU A 182 GLN A 187 1 6 HELIX 8 8 GLY A 190 VAL A 196 1 7 HELIX 9 9 GLY A 200 HIS A 221 1 22
SITE 1 AC1 19 ALA A 97 GLU A 100 PHE A 101 ARG A 104 SITE 2 AC1 19 TYR A 105 ALA A 108 LEU A 112 GLN A 115 SITE 3 AC1 19 VAL A 130 GLU A 133 LEU A 134 ASN A 140 SITE 4 AC1 19 TRP A 141 GLY A 142 ARG A 143 VAL A 145 SITE 5 AC1 19 ALA A 146 PHE A 195 TYR A 199
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000